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Unc-51 Like Kinase 1 (ULK1) is a critical regulator of the biogenesis of autophagosomes, the
central component of the catabolic macroautophagy pathway. Regulation of ULK1 activity
is dependent upon several phosphorylation events acting to repress or activate the enzy-
matic function of this protein. Phosphorylation of Ser758 ULK1 has been linked to repression
of autophagosome biogenesis and was thought to be exclusively dependent upon mTOR
complex 1 kinase activity. In the present study, a novel regulation of Ser758 ULK1 phospho-
rylation is reported following prolonged inhibition of the Parkinson’s disease linked protein
leucine rich repeat kinase 2 (LRRK2). Here, modulation of Ser758 ULK1 phosphorylation
following LRRK2 inhibition is decoupled from the repression of autophagosome biogenesis
and independent of mTOR complex 1 activity.
Introduction
Macroautophagy is a critical eukaryotic catabolic pathway, conserved from yeast through to humans that
allows the collection and degradation of cellular waste and contributes to maintenance of homoeostasis
[1]. The involvement of macroautophagy in several human diseases, ranging from cancer to neurodegen-
eration, has generated great interest in the pathways that control this process – with particular reference
to their utility as therapeutic targets [2,3]. As an important cellular process, macroautophagy is closely
monitored and regulated by a number of key signalling events, in particular the mammalian/mechanistic
target of rapamycin (mTOR) complex 1 (mTORC1), adenosine monophosphate-activated protein kinase
(AMPK) and the phosphoinositol 3 kinase (PI3K)/Beclin pathways. These pathways collectively monitor
the demand for autophagic vesicles based upon cellular conditions, and, in response, stimulate or repress
autophagosomes formation [4]. A key effector of the mTORC1-dependent regulation of macroautophagy
is Unc-51 like kinase 1 (ULK1). ULK1 is a 110 kDa serine/threonine kinase directly phosphorylated by
mTORC1 at multiple sites, among which is Ser758 [5]. mTORC1-dependent phosphorylation of Ser758
ULK1 acts to inhibit the initiation of phagophore formation, allowing activemTORC1 to repressmacroau-
tophagy.Upon inhibition ofmTORC1, for example, by treatmentwith rapamycin or torin-1, or by removal
of nutrients, Ser758 phosphorylation of ULK1 is reduced. This results in the activation of ULK1, and the
stimulation of the phagophore formation [6]. ULK1 is also subject to complex regulation by other sig-
nalling pathways, for example, the adenosine monophosphate-activated protein kinase (AMPK) pathway
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which targets multiple phosphorylation sites including Ser556 [7]. It is possible that other as yet unidentified sig-
nalling events [8] could act to regulate ULK1 activity via these identified phosphosites and others [9]. Previous re-
ports have implicated leucine rich repeat kinase 2 (LRRK2) in the regulation of macroautophagy [10-19]. LRRK2
is a multidomain enzyme containing both kinase and GTPase domains, mutations in which are the most common
cause of familial Parkinson’s disease (PD) [20,21]. Additionally, common non-coding polymorphisms at the LRRK2
locus have been identified in genome wide association studies (GWAs) that modestly increase the lifetime risk of PD
[22]. The most common familial mutation in LRRK2 (Gly2019Ser) has been demonstrated to increase LRRK2 kinase
activity [23], leading to the development of small chemical kinase inhibitors as potential therapeutics for PD. In the
present study, we show altered phosphorylation of ULK1 at Ser758 following prolonged inhibition of LRRK2. Our
results suggest that this alteration in phosphostate is (i) independent of mTORC1 activity and (ii) due to an as yet
unidentified kinase rather than a phosphatase. This implies Ser758 ULK1 phosphorylation is subject to regulation
by at least one signal transduction pathway in addition to mTOR, expanding the range of events able to control the
initiation of macroautophagy.
Experimental
Reagents
Chemical compounds were purchased as follows: LRRK2in1 [24] from the Division of Signal Transduction Therapy,
School of Life Sciences, University of Dundee, U.K.; GSK2578215A and MLi-2 from Tocris [25]; bafilomycin-A1
(B1793-2UG) and cycloheximide (01810-1G) from Sigma-Aldrich; torin-1 (CAY10997) from Cayman Chemicals.
Antibodies usedwere as follows: LC3 (NB100-2220, Novus Biologicals); total P70S6K (sc-8418, SantaCruz); phospho
Thr389 P70S6K (sc-11759, Santa Cruz); p62 (610833, BD Transduction Labs); total ULK1 antibody (8054 and 4773,
Cell Signalling); phospho Ser757 ULK1 antibody (6888 and D7O6UCell Signalling); phospho Ser555 ULK1 antibody
(5869, Cell Signalling); total LRRK2 antibody (MJFF2, Abcam); phosphor Ser935 LRRK2 antibody (UDD2, Abcam)
and β-actin (A1978, Sigma-Aldrich). AMPK activator (A769662) was kindly provided by Dr MPMS.
Cell culture and treatments
H4 cells (ATCC number HTB-148) were grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 10%
foetal calf serum (FCS). After 6 h fromplating,mediumwas changed and H4 cells were treatedwith LRRK2 inhibitors
LRRK2in1 or GSK2578215A, and/or with bafilomycin-A1 and/or torin-1 at the concentration and duration reported
in each experiment. Vehicle (dimethyl sulfoxide, DMSO) treated cells were used as controls. After incubation, cells
were washed in Dulbecco’s phosphate buffered saline (DPBS) and collected in a lysis buffer containing: 0.5% Triton
X-100, 2 mM ethylene di-amine tetra acetic acid (EDTA), 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulphate (SDS), protease inhibitors (cOmplete, protease inhibitor cocktail, Roche) and phosphatase inhibitors
(Halt phosphatase inhibitor cocktail, Pierce) in 50 mM Tris-HCl pH 7.5. m-TORC1 inhibition by starvation was
achieved by overnight serum deprivation followed by exposure to Earle’s balanced salts solution for 21/2 h before cell
lysis.
Primary astrocytes culture and treatments
Primary astrocytes from cortex were isolated from 3 days old rats. The tissue was mechanically dissociated and
trypsinized; the obtained cell pellet was plated in high glucose DMEM containing 20% FBS. At 7 days astrocytes
were washed in PBS, trypsinized and seeded 1:2 in new flasks and kept in culture by splitting 1:2 when at confluency.
Astrocytes were used for experiments after 14, 15 and 20 days in culture. They were seeded in six-well plates and
treated with LRRK2-in1 as described for H4 cells. Purity was accessed by staining with anti-GFAP antibody D1F4Q,
Cell Signalling.
Western blotting
Cell lysates were frozen immediately upon collection. Lysates were clarified immediately before use by centrifugation
at 10000 g for 5 min at 4◦C. Protein concentrations were assessed by bicinchoninic acid assay (BCAProtein Assay Kit,
Pierce) and 10–15 μg aliquots were separated by SDS polyacrylamide gel electrophoresis on Novex precast Bis-Tris
4–12% (Invitrogen), using MES running buffer (Invitrogen). After electrophoresis, gels were blotted onto 0.45 μm
cut-off, PVDF membranes (IPVH00010, Immobilon Millipore) and processed with antibodies diluted in Superblock
solution (Pierce). Films were acquired as images in jpg format using an EPSON Perfection 4870 photo scanner and
quantified using the ImageJ software (http://rsbweb.nih.gov/ij/).
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Statistics
Statistical analyses were performed using Prism software (GraphPad). Details of the statistics are included in each
figure legend. All the data are representative of results from at least three independent experiments. Quantification
of each Western blot was done relative the β-actin loading control. In the case of phospho proteins, to avoid protein
loss and degradation due to stripping procedures, all samples were run in two parallel gels. One gel was stained with
the total antibody and one gel with the anti-phosphorylated protein antibody, each signal was normalized for the own
β-actin loading control prior to normalization of phosphorylated protein over total. Comparison between different
gels was performed after normalization against the internal, DMSO treated, control.
Results
Prolonged induction of LRRK2-autophagy enhances phosphorylation of
ULK1 Ser758
As previously reported by our group, inhibition of the kinase activity of LRRK2 in the H4 astroglioma cell line results
inmTORC1 independent induction ofmacroautophagy [16,19].Confirmation of those experiments are reportedhere
by using three structurally distinct LRRK2 kinase inhibitors, LRRK2in1 (Figure 1A,B), GSK2578215A (Figure 1F–H)
and MLi-2 (Supplementary Figure S1). Inhibition of LRRK2 kinase activity in all cases resulted in modulation of
macroautophagy and increase in LC3-II levels. Co-treatment with LRRK2in1 and the lysosomal acidification blocker
bafilomycin-A1 [26] led to an additive increase in LC3-II (Figure 1D,E) confirming, as previously reported [16,19],
that LRRK2 inhibition results in induction of macroautophagy. Of note, no variation of total LRRK2 was observed
under this type of treatment (Supplementary Figure S1).
To assess a possible role for mTORC1/ULK1 in this increase in LC3-II following LRRK2 inhibition, we analysed
Ser758 phosphorylation of ULK1 both as function of dose and time of treatment. No changes in ULK1 phosphory-
lation were recorded up to 6/10 h of LRRK2 kinase inhibition (dose range 1–7.5 μM, Figure 1A–C). After 18 h of
treatment with LRRK2in1 (Figure 1B,C), GSK2578215A (Figure 1F–H) or MLi-2 (Supplementary Figure S1), there
was a significant and dose-dependent increase in Ser758 ULK1 phosphorylation concomitant with increased LC3-II
levels. This was confirmed in a second model system constituted by primary rat astrocytes (Figure 1I–N). Under the
same conditions, ULK1 phosphorylation on Ser556 was not significantly altered (Supplementary Figure S2). No in-
crease in LC3-II or Ser758 ULK1 phosphorylation was recorded after AMPK activation at variance with the results
obtained using LRRK2 inhibitors (Supplementary Figure S2). To control for off-targets effects, LRRK2 knockdown
cells were evaluated. A similar increase in Ser758 ULK1 phosphorylation was seen as a result of LRRK2 knockdown;
moreover, when LRRK2 knockdown cells were treated with LRRK2-in1 (Figure 2 and Supplementary Figure S3) or
MLi-2 (Supplementary Figure S1), no further increase in Ser758 ULK1 phosphorylation (over the already increased
basal level) was detected.
Hyper-phosphorylation of Ser758 ULK1 following LRRK2 kinase inhibition
is not dependent on m-TORC1
Ser758 ULK1 was previously reported to be exclusively phosphorylated mTORC1. To test whether mTORC1 was re-
sponsible for ULK1 phosphorylation during prolonged LRRK2 kinase inhibition, a co-treatment was performed.
In particular, LRRK2 was inhibited in parallel with mTOR inhibition by torin-1 or starvation. Both torin-1 and
starvation were able to induce macroautophagy via mTORC1 inhibition as verified by loss of phosphorylation on
P70S6K and ULK1 Ser758. The (18 h) co-treatment of cells with torin-1 and LRRK2in1 (Figure 3A) or starvation and
LRRK2in1 (Supplementary Figure S4) led to inhibition of mTOR (with loss of phosphorylation on P70S6K) while
Ser758 ULK1 remained phosphorylated. To further investigate whether a kinase or a phosphatase is involved in the
phosphorylation of ULK1 during LRRK2 inhibition, H4 cells were pre-treated with torin-1 for 4 h to completely
remove mTORC1-dependent phosphorylation on Ser758 ULK1. In this scenario, the restoration of ULK1 phospho-
rylation would be possible only through activation of a kinase. Primed cells were then treated for additional 18 h
with torin-1 alone or co-treatment with LRRK2in1. While torin-1-only treated cells continued to show no phospho-
rylation on Ser758 ULK1, H4 cells treated with LRRK2in1 were able to partially restore phosphorylation of Ser758
ULK1. Notably, this partial recovery of Ser758 ULK1 phosphorylationwas observed in the absence of activemTORC1
(Figure 3B).
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Figure 1. Prolonged inhibition of LRRK2 induces macroautophagy and ULK1 phosphorylation on Ser758
Six hours (A) and eighteen hours (B) LRRK2in1 treatment to inhibit LRRK2 kinase. The gels shown are representative of three
independent experiments. (C) Six, ten and eighteen hours of LRRK2in1 treatment, pSer758ULK1 was normalized against total
ULK1. Quantification was done for three independent experiments; after normalization against the control in DMSO, data were
pulled together in the dose–response curve (mean and standard error). Statistical analysis was performed with two-way ANOVA;
*P<0.05 and ***P<0.001. (D) Eighteen hours treatment with LRRK2in1 in the presence and absence of bafilomycin-A1 to block
the autophagy flux. The gel shown contains three replicates and is representative of three independent experiments as quantified
in (E) mean and standard deviation; statistical analysis was performed by one-way Anova followed by Tukey’s post-hoc test. (F)
Eighteen hours GSK2578215A treatment to inhibit LRRK2 kinase; the gel shown is representative of three independent experiments
and it is quantified in (G/H) with mean and standard deviation. (G) Ser758-ULK1 and total ULK1 were quantified against their own
β-actin loading control; then, Ser758-ULK1 was normalized against total ULK1. Statistical analysis was performed by unpaired,
Student’s t-test. (H) Ser556-ULK1 and total ULK1 were quantified against their own β-actin loading control; then, Ser556-ULK1
was normalized against total ULK1. Statistical analysis was performed by unpaired, Student’s t-test. (I and L) Eighteen hours
LRRK2in-1 treatment to inhibit LRRK2 kinase in primary rat astrocytes at 20 days in culture. The gels shown are representative of
three independent experiments (14, 15 and 20 days in culture) quantified in (M) and (N). (M and N) Ser758-ULK1 and total ULK1
were quantified against their own β-actin loading control; then, Ser758-ULK1 was normalized against total ULK1. Variation over
the control in DMSO (mean and standard deviation) is reported in the graphs Statistical analysis was performed by Student’s t-test;
*P<0.05, **P<0.01 and ***P<0.001.
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Figure 2. Results in LRRK2 knockdown H4 cells
H4 cells were transfected with 2–10 μg LRRK2 shRNA or scramble Open Biosystems GIPZ shRNAmir (V3LHS-644167, Thermo
Fisher Scientific) using Effectene (Qiagen) transfection reagent according to the manufacturer’s instructions. ShRNA vectors contain
a puromycin resistance gene. Cells were treated with 2 μg/ml puromycin supplemented DMEM 48 h after transfection and kept
under selection for expansion. Selection was removed 24 h before the experiment to avoid interference of the antibiotic with
the treatment. (A) Eighteen hours of LRRK2in1 treatment. The gel shown contains three replicates; it is representative of three
independent experiments and it is quantified in (B). (B) Ser758 ULK1and total ULK1 were first quantified against their own β-actin
loading control; then, Ser758 ULK1 was normalized against total ULK1 and variation was calculated against the scrambled control
in DMSO. Statistical analysis was performed by one-way ANOVA followed by Tukey’s post-hoc test. (C) Staining for LRRK2 with
the LRRK2 antibody MJFF#2, 3514-1/ab133474, Epitomics. The gel shown contains three replicates; it is representative of three
independent experiments quantified in (B). (D) LRRK2 was normalized against β-actin loading control; mean and standard deviation
are shown; statistical analysis was performed by unpaired, Student’s t-test. The knockdown led to a decrease in approximately
60% LRRK2 expression; *P<0.05 and **P<0.01.
Prolonged induction of LRRK2-autophagy leads to increase in ULK1 and
p62 synthesis
In addition to an increase in the proportion of ULK1 that is phosphorylated at Ser758, we observed a slight, but
significant, increase in total ULK1 levels after 18 h LRRK2 kinase inhibition (Figure 4A–C). To examine the origin of
this increase, we investigated whether levels of other autophagy proteins were modified. p62 levels were decreased as
expected afterm-TOR inhibition through torin-1 but were significantly increased after 18 h LRRK2 inhibition (Figure
4D,E). The increase in p62 levels was further enhanced by bafilomycin-A, confirming that p62 accumulation is a
function of induction rather than inhibition of macroautophagy. A similar increase in p62 was recorded after LRRK2
inhibition via GSK2578215A (Supplementary Figure S1) and upon LRRK2 knockdown (Figure 2 and Supplementary
Figure S3). Both the increase in total ULK1 and p62 levels were prevented by the use of cycloheximide to block de
novo protein synthesis (Figure 4F–H).
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 3. LRRK2in1 induces phosphorylation of Ser758 ULK1 independently of m-TOR
(A) Eighteen hours of LRRK2in1 treatment in the presence and absence of torin-1 to block m-TOR and induce de-phospho-
rylation of Ser758 ULK1 and Thr389 P70S6K. The gel shown is representative of three independent experiments, variation of
pSer758-ULK1/total ULK1 (mean and standard deviation) was quantified for each treatment versus the control in DMSO (DMSO
control = baseline, set to 1). Statistical analysis was performed by one-way ANOVA followed by Tukey’s post-hoc test. (B) Eighteen
hours of LRRK2in1 treatment after 4 h inhibition of m-TOR achieved by torin-1 treatment. The gel shown is representative of three
independent experiments, variation of pSer758-ULK1/total ULK1 (mean and standard deviation) was quantified for each treatment
versus the control in DMSO. Statistical analysis was performed by one-way ANOVA followed by Tukey’s post-hoc test; **P<0.01
and ***P<0.001.
Discussion
Macroautophagy is critical for cellular catabolism and tightly regulated by a number of signalling pathways. A central
event in the initiation of macroautophagy is the activation of ULK1, acting to stimulate the formation of the au-
tophagosome. This activation is driven by modulation of ULK1 phosphorylation, in particular by the kinases mTOR
(specifically mTORC1) and AMPK [9]. During investigations into the link between LRRK2 and control of macroau-
tophagy, an unexpected increase in phosphorylation of ULK1 at Ser785 was observed as a consequence of prolonged
inhibition of LRRK2 kinase activity.
Previous studies have demonstrated that inhibition of mTOR induces a rapid de-phosphorylation of Ser758 ULK1
leading to the activation of ULK1 and to the formation of a protein complex able to initiate the macroautophagy
cascade at the autophagosome assembly site [27]. In the present study, as expected based upon our current under-
standing of canonical macroautophagy, inhibition of mTOR by torin-1 or starvation led to dephosphorylation of
6 c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 4. Prolonged inhibition of LRRK2 induces increase production of ULK1 and p62
(A) Eighteen hours LRRK2in1 treatment to inhibit LRRK2 kinase. The gel shown is representative of three independent experiments,
each of them performed with three replicates. The graph in (B) and (C) show quantification of (A). Ser758 ULK1 and total ULK1 were
quantified against their own β-actin loading control; then, Ser758 ULK1 was normalized against total ULK1. Mean and standard
deviation are shown, statistical analysis was performed by ANOVA followed by Tukey’s post-hoc test. (D) Eighteen hours LRRK2in1
treatment to inhibit LRRK2 kinase or m-TOR inhibition by torin-1 in the presence and absence of bafilomycin-A1 to block autophagy.
The gel shown is representative of three independent experiments. The graph in (E) shows quantification of (D). p62 was quantified
againstβ-actin; mean and standard deviation are shown; statistical analysis was performed by ANOVA followed by Tukey’s post-hoc
test; **P<0.01 (F). Eighteen hours LRRK2in1 treatment to inhibit LRRK2 kinase in the presence and absence of cycloheximide to
block protein synthesis. The gel shown is representative of three independent experiments, each of them performed with three
replicates. p62 and total ULK1 were quantified against β-actin in (G) and (H) respectively. Mean and standard deviation are shown;
statistical analysis was performed by ANOVA followed by Tukey’s post-hoc test; *P<0.05, **P<0.01 and ***P<0.001; ns = not
significant.
ULK1 on Ser758. In contrast with mTOR inhibition, no changes in Ser758 ULK1 were visible after 6/10 h LRRK2 ki-
nase inhibition, even if LC3-II levels increased due to induction of macroautophagy as demonstrated by co-treatment
with bafilomycin-A1. However, after prolonged LRRK2 kinase inhibition, a significant increase in phosphorylation
on Ser758 ULK1 was recorded. These data suggest that (i) induction of macroautophagy through LRRK2 inhibition
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 5. Schematic representation of the hypothetic involvement of LRRK2 in macroautophagy
Inhibition of mTORc1 kinase activity results in the activation of ULK1 and consequent induction of macroautophagy. Inhibition
of LRRK2 kinase activity leads to increase in the production of autophagosomes by activation of an unknown effector which is
not ULK1. Prolonged inhibition of LRRK2 kinase and/or a chronic excess in macroautophagy induction activate a feedback loop
responsible for repression of ULK1 by means of activation of an unknown kinase which is not mTOR.
does not involve the dephosphorylation of ULK1 and (ii) a regulatory feedback loop is activated to repress ULK1
activity, and therefore canonical macroautophagy, by hyper-phosphorylation of Ser758 ULK1 following chronic in-
duction of macroautophagy through LRRK2 (Figure 5). Of note, the use of three different LRRK2 kinase inhibitors
and the use of a control set in which LRRK2 has been knocked down in H4 cells are suggestive that a non-canonical
macroautophagy pathwaymediated by LRRK2may be at work. However, the final confirmation can be only obtained
in an idealmodel system inwhichmTOR itself (or the components of its complex) are knocked down.ULK1 is known
to be regulated by complex phosphorylation events [8], some of which, to date, have not been exhaustively character-
ized. It is believed that Ser758 is targeted solely by mTORC1, while phosphatases targeting ULK1 at residue Ser758
have yet to be characterized [28]. We investigated whether this phosphorylation event on Ser758 ULK1 was likely
to be controlled by a kinase (positive induction of phosphorylation) or a phosphatase (repression of ULK1 dephos-
phorylation). Experiments performed with cells that had been pre-treated with torin-1 to inactivate mTORC1 (and
thence reduce phosphorylation of ULK1 Ser758) prior to LRRK2 inhibition showed that, once phosphorylation of
ULK1 Ser758 by mTORC1 is lost, it can be partially restored by a putative negative feedback loop induced by chronic
LRRK2 inhibition. In this scenario, restoration of ULK1 phosphorylation is achievable only if a kinase distinct from
mTORC1 acts upon this site. If the phosphorylation event on Ser758 ULK1 (following inhibition of LRRK2) was
controlled by the inhibition of a phosphatase, this would have not occurred under these conditions. Taken together,
these data imply that the feedback loop on Ser758 is likely to be mTOR independent and subject to the activity of
an as yet unidentified kinase activity, distinct from mTOR, rather than by the inhibition of a phosphatase. An addi-
tional consequence of prolonged inhibition of LRRK2 was an increase in the total amount of ULK1 and p62. This
phenomenon was prevented by the inhibition of protein synthesis by cycloheximide, thus suggesting involvement
of transcriptional/translational effects. Changes in total ULK1 levels were not recorded in LRRK2 knockdown cells,
suggesting they can be the result of autophagy induction rather than the direct block of LRRK2; indeed, changes in
ULK1 expression during endoplasmic reticulum (ER) stress and hypoxia have been previously documented [29,30].
Increase in p62 was detected in LRRK2 knockdown cells suggesting it may be, at least in part, direct consequence of
LRRK2 kinase inhibition. A wide range of transcription factors are known to modulate expression level of autophagy
proteins indicating that macroautophagy can be modulated by transcriptional feedback loops [31].
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The data presented here confirm that LRRK2 has a role in the regulation of macroautophagy in astrocytes and
supports a model where prolonged inhibition of LRRK2 kinase activity stimulates multiple feedback loops acting
to repress canonical macroautophagy. Regulation of autophagy through feedback loops activated to maintain cel-
lular homoeostasis is already documented [32]; the additional feedback loop following LRRK2 kinase inhibition we
present here raises the possibility that chronic use of LRRK2 inhibitorsmay result in deregulation ofmacroautophagy,
highlighting that this catabolic process should be carefully monitored in pre-clinical evaluation of LRRK2 inhibition.
Moreover, it suggests the existence of a non-canonical regulatory pathway directly impacting on ULK1 – indepen-
dent of mTORC1 and, potentially, AMPK. Given the importance of macroautophagy in a host of human disorders,
its status as a drug discovery target pathway, and the fundamental role that it places in cellular homoeostasis, further
studies leading to the identification of the protein kinase responsible for this regulatory event have the potential to
add to the range of drug targets available for the modulation of this process.
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